Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo.

Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y.

Neurosci Lett. 2009 Jan 23;450(1):51-5. doi: 10.1016/j.neulet.2008.11.023. Epub 2008 Nov 13.

PMID:
19022346
2.

Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.

Zhang Q, Zhang X, Sun A.

Acta Neuropathol. 2009 Jun;117(6):687-97. doi: 10.1007/s00401-009-0491-6. Epub 2009 Feb 4.

PMID:
19190923
3.

Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH.

Brain Res Mol Brain Res. 2005 Aug 18;138(2):135-44.

4.

Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.

Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA.

J Biol Chem. 2013 Feb 8;288(6):4056-65. doi: 10.1074/jbc.M112.393751. Epub 2012 Dec 21.

5.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

6.

Selenomethionine ameliorates cognitive decline, reduces tau hyperphosphorylation, and reverses synaptic deficit in the triple transgenic mouse model of Alzheimer's disease.

Song G, Zhang Z, Wen L, Chen C, Shi Q, Zhang Y, Ni J, Liu Q.

J Alzheimers Dis. 2014;41(1):85-99. doi: 10.3233/JAD-131805.

PMID:
24577479
7.

Fluorocitrate induced the alterations of memory-related proteins and tau hyperphosphorylation in SD rats.

Shang XL, Wang QB, Liu XP, Yao XQ, Cao FY, Wang Q, Zhang JY, Wang JZ, Liu GP.

Neurosci Lett. 2015 Jan 1;584:230-5. doi: 10.1016/j.neulet.2014.10.036. Epub 2014 Oct 28. Erratum in: Neurosci Lett. 2015 Mar 4;589:196.

PMID:
25449869
8.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674
9.

Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.

Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, Hutton M, Dickson D, Yen SH.

J Neurochem. 2004 Aug;90(4):829-38.

10.

Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.

Amadoro G, Corsetti V, Atlante A, Florenzano F, Capsoni S, Bussani R, Mercanti D, Calissano P.

Neurobiol Aging. 2012 Apr;33(4):833.e1-25. doi: 10.1016/j.neurobiolaging.2011.08.001. Epub 2011 Sep 29.

PMID:
21958963
11.

Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.

Padmanabhan J, Levy M, Dickson DW, Potter H.

Brain. 2006 Nov;129(Pt 11):3020-34. Epub 2006 Sep 20.

PMID:
16987932
12.

Overexpression of 14-3-3z promotes tau phosphorylation at Ser262 and accelerates proteosomal degradation of synaptophysin in rat primary hippocampal neurons.

Qureshi HY, Han D, MacDonald R, Paudel HK.

PLoS One. 2013 Dec 19;8(12):e84615. doi: 10.1371/journal.pone.0084615. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e102932.

13.

Inflammation induced by infection potentiates tau pathological features in transgenic mice.

Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM.

Am J Pathol. 2011 Jun;178(6):2811-22. doi: 10.1016/j.ajpath.2011.02.012. Epub 2011 Apr 30.

14.

Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice.

Joshi YB, Chu J, Praticò D.

Aging Cell. 2013 Aug;12(4):706-11. doi: 10.1111/acel.12096. Epub 2013 Jun 11.

15.

Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia.

Planel E, Bretteville A, Liu L, Virag L, Du AL, Yu WH, Dickson DW, Whittington RA, Duff KE.

FASEB J. 2009 Aug;23(8):2595-604. doi: 10.1096/fj.08-122424. Epub 2009 Mar 11.

16.

HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.

Sepulveda-Diaz JE, Alavi Naini SM, Huynh MB, Ouidja MO, Yanicostas C, Chantepie S, Villares J, Lamari F, Jospin E, van Kuppevelt TH, Mensah-Nyagan AG, Raisman-Vozari R, Soussi-Yanicostas N, Papy-Garcia D.

Brain. 2015 May;138(Pt 5):1339-54. doi: 10.1093/brain/awv056. Epub 2015 Apr 4.

PMID:
25842390
17.

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J.

Cell. 2010 Aug 6;142(3):387-97. doi: 10.1016/j.cell.2010.06.036. Epub 2010 Jul 22.

18.

NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.

Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D.

Aging Cell. 2013 Feb;12(1):11-23. doi: 10.1111/acel.12018. Epub 2012 Nov 23.

19.

Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J.

Am J Pathol. 2009 Jan;174(1):228-38. doi: 10.2353/ajpath.2009.080764. Epub 2008 Dec 12.

20.

Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.

Shan Y, Wang DD, Xu YX, Wang C, Cao L, Liu YS, Zhu CQ.

J Alzheimers Dis. 2016;49(3):829-44. doi: 10.3233/JAD-150486.

PMID:
26577520

Supplemental Content

Support Center